{"id":473951,"date":"2020-03-16T08:40:02","date_gmt":"2020-03-16T08:40:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=473951"},"modified":"2020-03-16T08:40:02","modified_gmt":"2020-03-16T08:40:02","slug":"multiple-myeloma-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/multiple-myeloma-market-insight-market-size-epidemiology-leading-companies-emerging-and-marketed-therapies-by-delveinsight_473951.html","title":{"rendered":"Multiple Myeloma Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight"},"content":{"rendered":"
\"Multiple<\/a><\/p>\n
\n
Multiple Myeloma Market Insight Report<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. <\/div>\n

Albany, US –<\/strong> DelveInsight has launched a new report on <\/strong>Multiple Myeloma Market Insights, Epidemiology and Market Forecast-2030  <\/strong><\/p>\n

The Multiple Myeloma market report<\/a> provides current treatment practices, emerging drugs, Multiple Myeloma market share of the individual therapies, current and forecasted Multiple Myeloma<\/strong> Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

 <\/p>\n

Key benefits of the report
<\/strong>1. Multiple Myeloma market report covers a descriptive overview and comprehensive insight of the Multiple Myeloma epidemiology and Multiple Myeloma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Multiple Myeloma market report provides insights on the current and emerging therapies.
3. Multiple Myeloma market report provides a global historical and forecasted market covering drug outreach in 7 MM.   
4. Multiple Myeloma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Multiple Myeloma market.<\/p>\n

“Males develop Multiple Myeloma more likely than females.”<\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/multiple-myeloma-market<\/a><\/p>\n

             \"\"<\/strong><\/p>\n

Multiple Myeloma is a malignant disease that is characterized by the growth of clonal plasma cells in the bone marrow, and the secretion of monoclonal immunoglobulins typically accompanies them.<\/p>\n

The researchers have identified the bone marrow-support tissues and bone cells produce growth factors that lead to the myeloma cells growth. The myeloma cells make substances, which cause bone cells to face changes that debilitate the bones. These discoveries are benefiting researchers to develop new drugs for blocking these growth factors, slow down cancer, and reduce bone destruction. The types of systemic therapies used for multiple Myeloma are:<\/p>\n

Targeted therapy is a treatment that aims cancer’s specific genes, proteins, or the tissue environment. This type of treatment impedes the growth and spread of cancer cells while avoiding damage to healthy cells. Recently, targeted treatment, sometimes called novel therapy, has proven to be increasingly successful at controlling Myeloma and improving prognosis. Targeted therapy for multiple Myeloma includes Lenalidomide, daratumumab, bortezomib.<\/p>\n

Although Multiple Myeloma is rarely curable, it is a highly manageable disease. Overall, the prognosis, or predicted course of the disease, for patients with Multiple Myeloma has improved dramatically in the past decade due to continuing research. The prognosis (predicted course of the disease) of multiple Myeloma is usually based on the existence of different signs, symptoms, and circumstances, such as your age. Another critical factor is the stage of the disease as determined by the results of diagnostic testing. The patient needs to undergo all of the appropriate tests for the early diagnosis. Many of these tests are also used to assess the extent of disease and to plan and monitor treatment. Overall, the rise in Multiple Myeloma patient population increased funding by governmental bodies, and vigorous R&D activities are further anticipated to propel Multiple Myeloma market during the forecast period (2020–2030).<\/p>\n

Drugs covered<\/strong><\/p>\n

1. GSK2857916<\/p>\n

2. Isatuximab<\/p>\n

3. MOR202<\/p>\n

And many others<\/p>\n

 <\/p>\n

The key players in Multiple Myeloma market are:<\/strong><\/p>\n

1. GlaxoSmithKline<\/p>\n

2. Sanofi<\/p>\n

3. MorphoSys<\/p>\n

And many others<\/p>\n

 <\/p>\n

Table of contents<\/strong><\/p>\n

1. Report Introduction<\/p>\n

2. Executive Summary<\/p>\n

3. SWOT Analysis<\/p>\n

4. Multiple Myeloma Market Overview at a Glance<\/p>\n

5. Multiple Myeloma Disease Background and Overview<\/p>\n

6. Multiple Myeloma Epidemiology and Patient Population<\/p>\n

7. Country- Wise Multiple Myeloma Epidemiology<\/p>\n

7.1. United States<\/p>\n

7.2. EU-5<\/p>\n

7.2.1. Germany<\/p>\n

7.2.2. France<\/p>\n

7.2.3. Italy<\/p>\n

7.2.4. Spain<\/p>\n

7.2.5. United Kingdom<\/p>\n

7.3. Japan<\/p>\n

8. Multiple Myeloma Treatment & Medical Practices<\/p>\n

9. Patient Journey<\/p>\n

10. Multiple Myeloma Marketed Drugs<\/p>\n

10.1. Darzalex (daratumumab): Janssen Biotech<\/p>\n

10.2. Velcade (Bortezomib): Millennium Pharmaceutical<\/p>\n

10.3. Revlimid (lenalidomide): Celgene Corporation<\/p>\n

11. Multiple Myeloma Key Emerging Therapies<\/p>\n

11.1. GSK2857916: GlaxoSmithKline<\/p>\n

11.2. Isatuximab: Sanofi<\/p>\n

11.3. MOR202: MorphoSys<\/p>\n

12. Attribute Analysis<\/p>\n

13. Multiple Myeloma Market Size<\/p>\n

14. 7MM Multiple Myeloma: Country-Wise Market Analysis<\/p>\n

14.1. United States<\/p>\n

14.2. Germany<\/p>\n

14.3. France<\/p>\n

14.4. United Kingdom<\/p>\n

14.5. Spain<\/p>\n

14.6. Italy<\/p>\n

14.7. Japan<\/p>\n

15. Market Access and Reimbursement<\/p>\n

16. Market Drivers<\/p>\n

17. Market Barriers<\/p>\n

18. Appendix<\/p>\n

19. Multiple Myeloma Report Methodology<\/p>\n

20. DelveInsight Capabilities<\/p>\n

21. Disclaimer<\/p>\n

22. About DelveInsight<\/p>\n

Request for sample pages here -> https:\/\/www.delveinsight.com\/sample-request\/multiple-myeloma-market<\/a><\/p>\n

Related Reports:<\/strong><\/p>\n